Navigation Links
Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent
Date:2/16/2012

ticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2010, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

 


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
2. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
3. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
4. Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation
5. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
6. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
9. Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System
10. China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Companys Convertible Notes in August 2008
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... , Sept. 4, 2015  Cumberland Pharmaceuticals (CPIX), today ... present live at VirtualInvestorConferences.com on September 10, 2015. ... ET LINK: http://tinyurl.com/sep10pre ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:9/4/2015)... DUBLIN , Sept. 4, 2015  Allergan plc (NYSE: ... that Brent Saunders , CEO and President of Allergan, ... at the Morgan Stanley Global Healthcare Conference 2015 in ... http://photos.prnewswire.com/prnh/20150612/222796LOGO The presentation will take ... Time at the Grand Hyatt New York, 109 East 42nd ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3
... Lilly and Company announced today that Phase III trial ... for injection) to the current standard of care provided ... years for women with locally advanced cervical cancer. ... women,s cancer, and the second most common cause of ...
... and SOUTH SAN FRANCISCO, Calif. , May 30 ... carfilzomib solid tumor program in an oral presentation at ... Oncology (ASCO) in Orlando, Florida. Data from a ... trial of carfilzomib in relapsed patients with advanced solid ...
Cached Medicine Technology:Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting 2Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting 3Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting 4
(Date:9/4/2015)... , ... September 04, 2015 , ... The USC Eye ... ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored to ... pride in the quality of our ophthalmology residency program. Our faculty places a high ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in ... in the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 ... Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC Championship ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers deal with ... the Stark physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices ... Services, Inc. (AIS), will detail which deals are attracting the most government scrutiny ...
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, the online retail ... cannot be passed up. FiltersFast.com, will ship all orders over $50.00 for ... product replacements. Take advantage of this promotion now through September 8, 2015. , ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... Vermont have uncovered the possible causes for brain disorders ... were// published November 1, 2006 in the prestigious journal ... for signaling regional blood flow changes in the brain. ... uninterrupted supply of oxygen and glucose, which is provided ...
... alcohol heavily over a short period of time or drink ... to face more depression than men, says a study.// ... Of Medicine and Health Sciences and other researchers studied the ... history of depression, according to the online edition of BBC ...
... Scientists have now uncovered graphic evidence that suggests a ... occurrence of herpes simplex infection//. The journal, Neurobiology of ... older individuals, the same gene is implicated in causing ... interest to the scientific world. It raises the possibility ...
... A compound derived from the bark of a tree could help ... new study.// ,The new molecule tazopsine was isolated ... science portal SciDev Net. ,Madagascar is an island ... It is the fourth largest island in the world and is ...
... before and for 24 hours after stent placement or ... any significant// treatment effect compared to placebo, according to ... had shown promise in preliminary studies. ,Acute ST-elevation ... following a heart attack) is a major public health ...
... issue of the Journal of the National Cancer Institute, the ... 2005 was $2.3// billion in the first year after diagnosis. ... of cancer care, but few have attempted to include a ... traveling to and from care, waiting for appointments, and receiving ...
Cached Medicine News:Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 3Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 4Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4Health News:Drug Therapy Offers Little Benefit for Some Patients Undergoing Angioplasty or Stent Procedure 2Health News:Cancer Care-Patient's Time Costs Studied 2
... the M3 and M4 monitors offer wireless ... care. M Series monitors are equipped with ... set of non-invasive parameters and input for ... extensions offer Mainstream or Microstream® CO 2 ...
Compact networked patient monitors for flexible care....
... on Philips strong heritage in patient monitoring, ... extensive clinical measurements menu; built-in clinical support ... 12-lead ECG, and arrhythmia analysis; and many ... to use and operates on a networked ...
... expands hospital-grade monitoring capabilities into the growing ... disease state management. The system is ... full range of clinical applications, from continuous ... to periodic monitoring of patients outside the ...
Medicine Products: